申请人:TAKEDA PHARMACEUTICALS CO
公开号:WO2017038909A1
公开(公告)日:2017-03-09
The present invention provides a heterocyclic compound a TLR7 and/or TLR9 and/or TLR-7/8/9 and/or TLR-7/8 and/or TLR-7/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases and/or inflammatory diseases and the like, in particular, acute decompensated heart failure, non-alcoholic steatohepatitis (NASH), IgA nephropathy, Duchenne muscular dystrophy (DMD), systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, transplant rejection and graft-versus-host disease, hepatocellular carcinoma (HCC) and the like. The present invention is a compound represented by the formula (1) : wherein each symbol is as described in the specification, or a salt thereof.
本发明提供了一种杂环化合物,具有TLR7和/或TLR9和/或TLR-7/8/9和/或TLR-7/8和/或TLR-7/9的抑制作用,可用作自身免疫疾病和/或炎症性疾病等的预防或治疗剂,特别是急性失代偿性心力衰竭、非酒精性脂肪肝炎(NASH)、IgA肾病、杜兴氏肌肉萎缩症(DMD)、系统性红斑狼疮、干燥综合征、类风湿关节炎、银屑病、炎症性肠病、哮喘、1型糖尿病、重症肌无力、造血功能障碍、B细胞恶性肿瘤、移植排斥和移植物抗宿主病、肝细胞癌(HCC)等。本发明是一种由式(1)表示的化合物:其中每个符号如说明书中所述,或其盐。